Enferm Infecc Microbiol Clin. 2017;35(1):37–40

Enfermedades Infecciosas y Microbiología Clínica

www.elsevier.es/eimc

Brief report

Assessment of biofilm production in *Candida* isolates according to species and origin of infection

María Guembe[a,*], Raquel Cruces[a], Teresa Peláez[a,b], Patricia Muñoz[a,b,c], Emilio Bouza[a,b,c], on behalf of the GEIDI study group

[a] *Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain*
[b] *Medicine Department, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain*
[c] *CIBER de Enfermedades Respiratorias (CIBERES CD06/06/0058), Palma de Mallorca, Spain*

ARTICLE INFO

Article history:
Received 29 December 2015
Accepted 2 April 2016
Available online 9 May 2016

Keywords:
Candida
Biofilm production
Clinical samples
Crystal violet binding assay
Cut-off

ABSTRACT

The biofilm production (BP) of 200 clinical strains of *Candida* isolated during 2010–2013 were assessed using an in vitro model and a comparison of the results was made between species and between origins of the infections. The BP was assessed using the crystal violet assay, and the strains were classified as low, moderate, or high biofilm producers. *Candida tropicalis* had the highest values for BP, which varied depending on the origin of the infection. Assessment of BP is a key diagnostic tool that enables us to better understand *Candida* infections.

Determinación de la producción de biopelícula en aislados de *Candida* de acuerdo con las especies de *Candida* y el origen de la infección

Palabras clave:
Candida
Producción de biopelícula
Muestras clínicas
Tinción cristal violeta
Punto de corte

RESUMEN

Desde 2010 a 2013 evaluamos la producción de biopelícula (PB) en 200 cepas clínicas de *Candida* y comparamos los resultados de las especies de *Candida* entre los orígenes de la infección mediante un modelo in vitro. La PB se determinó con el ensayo de cristal violeta y las cepas se clasificaron como baja, moderada o altamente productoras de biopelícula. *C. tropicalis* tuvo los valores más altos de PB, y la PB en *Candida* varió dependiendo del origen de la infección. La determinación de la PB es una herramienta diagnóstica importante para entender mejor las infecciones por *Candida*.

Introduction

Candida albicans is the most common cause of oropharyngeal and cutaneous candidiasis, and non-*albicans* species are increasingly associated with invasive candidiasis.[1] *Candida* bloodstream infection is one of the main nosocomial infections, with high morbidity and mortality. The ease with which some *Candida* strains adhere to natural or artificial surfaces to create aggregates (biofilm) increases their virulence and the likelihood of chronic infection.[2]

Biofilm production (BP) by *Candida* species has been assessed mainly using the crystal violet binding assay. However, most studies report BP without a standard cut-off and are generally based on *Candida* species isolated from patients with candidemia.[3–6] Data regarding BP in *Candida* species isolated from different sites are scarce.

Our objective was to test BP in clinical strains of *Candida* and compare the results between *Candida* species and between different sites of infection.

* Corresponding author.
E-mail address: mariaguembe@hotmail.com (M. Guembe).

http://dx.doi.org/10.1016/j.eimc.2016.04.003

Methods

We performed a prospective in vitro study of BP in 200 clinical strains of *Candida* species isolated from 155 patients admitted to our institution during 2010–2013. The *Candida* species were distributed as follows: *C. albicans*, 41 (20.5%); *C. parapsilosis*, 40 (20.0%); *C. krusei*, 40 (20.0%); *C. glabrata*, 39 (19.5%); *C. tropicalis*, 22 (11.0%); and *C. guilliermondii*, 18 (9.0%). The sources of the *Candida* isolates were as follows: urine, 33 (16.5%); biopsy specimens, 28 (14.0%); respiratory tract, 26 (13.0%); blood, 24 (12.0%); sterile liquids, 18 (9.0%); wound, 13 (6.5%); abscess, 10 (5.0%); catheter, 8 (4.0%); prosthetic material, 3 (1.5%); and other, 37 (18.5%).

The yeasts were identified using the ID 32C system (bioMérieux).

BP was assessed using the crystal violet binding assay.[3,7]

Laboratory procedure

Isolates were grown on Sabouraud dextrose agar for 24 h at 37 °C. Two or three colonies from each plate were inoculated into 20 mL of yeast peptone dextrose (YPD) medium and incubated for 18 h at 30 °C on an orbital shaker. They were then centrifuged at 3500 rpm for 5 min, washed twice with 10 mL of phosphate-buffered saline, and re-suspended in RPMI 1640 medium. After being standardized to 1×10^6 CFU/mL in RPMI, 100 μL of the suspension was placed in the wells of a 96-well, flat-bottomed microtiter plate and incubated for 24 h at 37 °C. The suspensions were discarded, and the wells were washed 3 times with sterile phosphate-buffered saline and filled with crystal violet for 15 min. The wells were then washed and the residue solubilized with acetic acid. The suspension was transferred to clean wells, and absorbance was detected in the spectrophotometer at 550 nm. Each experiment was performed in triplicate, and the average value was used for the analysis.

Statistical analysis

The qualitative variables appear with their frequency distributions. Values for continuous variables are expressed as the mean (SD) with a 95% confidence interval (95% CI) when applicable. Categorical variables were evaluated using the chi-square or 2-tailed Fisher exact test. Normally distributed continuous variables were compared using the *t* test. We determined the cut-offs for BP using a ROC curve. The Games–Howell test was used to compare BP between the species and between the types of samples. The comparison between BP and origin of the infection was made irrespective of the *Candida* species.

Statistical significance was set at $p < 0.05$ (2-tailed). All statistical tests were performed using SPSS version 21.0.

Ethics

The study was approved by the local ethics committee.

Results

Of the 155 patients, 129 (83.2%) had only 1 *Candida* species isolated in 1 clinical specimen and 26 (16.8%) had 2 or more isolates at the same or different sites (mean [SD] no. of isolates per patient, 1.26 [0.75]). Only 6 patients (3.9%) had the same *Candida* species in different clinical specimens.

After the analysis using the crystal violet assay, we determined the following cut-offs for BP in *Candida* strains: low, <1; moderate, 1–2; and high, >2.

BP was low in 53.0% of isolates, moderate in 24.0%, and high in 23.0%. The mean (SD) BP for the different *Candida* species was as follows: *C. albicans*, 1.8 (0.5); *C. parapsilosis*, 1.3 (0.9); *C. krusei*, 0.4 (0.3); *C. glabrata*, 0.3 (0.4); *C. tropicalis*, 2.4 (0.7); and *C. guilliermondii*, 0.6 (0.5) (Table 1 and Fig. 1). Analysis of the degree of BP in the different *Candida* species showed that most *C. albicans* were high or moderate biofilm producers (92.6%) and that *C. parapsilosis* were mainly low or moderate biofilm

Table 1
Description of biofilm production according to *Candida* spp. and clinical specimens.

Specie (*n*, %)	BP				*p*
	Mean (SD)	Low[a] *N* (%)	Moderate[b] *N* (%)	High[c] *N* (%)	
					<0.001
C. albicans (41, 20.5)	1.8 (0.5)	3 (7.3)	19 (46.3)	19 (46.3)	
C. parapsilosis (40, 20.0)	1.3 (0.9)	15 (37.5)	14 (35.0)	11 (27.5)	
C. krusei (40, 20.0)	0.4 (0.3)	37 (92.5)	3 (7.5)	0 (0.0)	
C. glabrata (39, 19.5)	0.3 (0.4)	36 (92.3)	3 (7.7)	0 (0.0)	
C. tropicalis (22, 11.0)	2.4 (0.7)	1 (4.5)	5 (22.7)	16 (72.7)	
C. guilliermondii (18, 9.0)	0.6 (0.5)	14 (77.8)	4 (22.2)	0 (0.0)	
Clinical specimens (n, %)					
					<0.001
Urine (33, 16.5)	0.8 (0.7)	21 (63.6)	9 (27.3)	3 (9.1)	
Biopsy (28, 14.0)	1.5 (0.8)	8 (28.6)	10 (35.7)	10 (35.7)	
Respiratory tract (26, 13.0)	0.4 (0.4)	24 (92.3)	1 (3.8)	1 (3.8)	
Blood (24, 12.0)	1.4 (0.9)	8 (33.3)	8 (33.3)	8 (33.3)	
Normally sterile fluids (18, 9.0)	1.6 (1.1)	6 (33.3)	4 (22.2)	8 (44.4)	
Wound (13, 6.5)	0.9 (0.8)	9 (69.2)	3 (23.1)	1 (7.7)	
Abscess (10, 5.0)	1.3 (1.0)	5 (50.0)	2 (20.0)	3 (30.0)	
Catheter (8, 4.0)	1.7 (0.6)	2 (25.0)	2 (25.0)	4 (50.0)	
Prosthetic material (3, 1.5)	1.8 (0.8)	0 (0.0)	2 (66.7)	1 (33.3)	
Other (37, 18.5)	0.9 (0.8)	23 (62.2)	7 (18.9)	7 (18.9)	
Total (200)		106 (53.0)	48 (24.0)	46 (23.0)	

BP, biofilm production; SD, standard deviation.
[a] Low, <1.
[b] Moderate, 1–2.
[c] High, >2.